



Suite 202 279 Midpark Way SE Calgary AB T2X 1M2 P 403.254.9252 F 403.256.8495 info@resverlogix.com For Immediate Release TSX Symbol: RVX

## **Resverlogix Announces Live Web Cast Update**

CALGARY, AB, February 22, 2006 – Resverlogix Corp. ("Resverlogix") (TSX: RVX), announced today that it will be hosting a live Vcall web cast on Thursday February 23<sup>rd</sup> at 11:00am MST. The web cast will allow securities analysts, shareholders and other key stakeholders the opportunity to hear management discuss the company's strategic objectives for 2006 and corporate updates in regards to its ongoing licensing negotiations for its ReVas<sup>™</sup> program.

The call is being webcast by Vcall and can be accessed at a link provided on "Resverlogix's" website at <a href="https://www.resverlogix.com">www.resverlogix.com</a>. Investors can also access the webcast at <a href="https://www.lnvestorCalendar.com">www.lnvestorCalendar.com</a>. The web cast will be available on our website for replay throughout 2006.

The web cast link will be posted on the Resverlogix web site <a href="www.resverlogix.com">www.resverlogix.com</a> prior to the event.

## About Resverlogix Corp.

Resverlogix Corp. is a Canadian biotechnology company engaged in the discovery and development of biopharmaceuticals. Combining expertise with innovation, Resverlogix's lead technology NEXVAS<sup>TM</sup>, applies advanced medical research to develop therapies that increase high density lipoprotein (HDL), the "good cholesterol," to treat cardiovascular diseases (CVD). The Company's second CVD research program ReVas<sup>TM</sup> is dedicated to developing novel compounds for acute based drug therapy via a medical device. Resverlogix Corp. is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the TSX Exchange under the symbol RVX. For further information, please visit our web site at: <a href="https://www.resverlogix.com">www.resverlogix.com</a>.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

## For further information please contact:

Donald J. McCaffrey

President/CEO Resverlogix Corp.

Phone: 403-254-9252 ext. 223

Fax: 403-256-8495

Email: don@resverlogix.com

Kenneth Lebioda

Vice President Business Development

Resverlogix Corp.

Phone: 403-254-9252 ext. 227

Fax: 403-256-8495

Email: ken@resverlogix.com